ELEVANCE HEALTH INC (ELV)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for ELV
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ELV | Director; Chair | 64 | ["CEO", "COO/Executive Leadership", "Finance/Capital Markets", "Healthcare Industry", "Regulatory/Public Policy", "Diversity"] | ["Compensation and Talent", "Governance"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| GH | Director; Chief Executive Officer | 60 | ["Chief Executive Officer of Immunocore Limited since January 2019","Member of the boards of directors of Immunocore Limited since January 2019","Member of the board of directors of Anthem, Inc. since February 2018","Audit committee member for Anthem","Past President of the Association for Women in Science","Executive Vice President of AstraZeneca PLC from October 2013 to January 2019","President of MedImmune from January 2013 to January 2019","Senior Vice President, Research and Development at MedImmune from 2010 to 2013","Ph.D. in physiology and DEA in physiology and biology from the Université de Paris VI","AEA in plant physiology and M.S. in biology from the Université de Paris VII"] | ["Audit Committee","Nominating and Corporate Governance Committee"] | 2022 |
Biography sourced from the proxy statement filing.
Ms. Jallal brings extensive CEO, healthcare industry and finance experience to the Board gained through her current CEO position at a multinational, biotechnology company, as well as several former leadership positions at biopharmaceutical companies, including as President at a biologic research and development subsidiary of a large public company. Her current CEO position and other former executive positions also provide her with regulatory and public policy experience due to the highly-regulated nature of the biopharmaceutical and biotechnology industries. Professional and Other Experience: Immunocore Holdings plc, a T-cell receptor biotechnology company, CEO (since 2019) AstraZeneca PLC ( AstraZeneca ), a pharmaceutical and biopharmaceutical business, Executive Vice President (2013-2019) MedImmune, a biotechnology business and a subsidiary of AstraZeneca, President (2013-2019), Executive Vice President, Research and Development (2010-2013) and various other research and development positions (2006-2010) Other Public Board Service: Immunocore Holdings plc, Director (since 2019) ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company (publicly traded beginning 2024), Director (2022-2024) Guardant Health, Inc., a precision oncology company, Director (2019-2022) Age: 64 Director Since: 2018 Committees: Compensation and Talent Governance (Chair) Skills, Experiences and Attributes: CEO COO/Executive Leadership Finance/Capital Markets Healthcare Industry Regulatory/Public Policy Diversity Education: M.S. and Ph.D., I Universite De Paris VI; Fellow, Max Planck Institute of Biochemistry